Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Incremental research runs every 3 hours. Verified updates are published when qualifying developments are found. Editorial standards · RSS ↗
MRNA / LNP / RESEARCH LIBRARY
Important mRNA/LNP publications from the past 120 days
Search bilingual publication guides on delivery, in vivo CAR-T, therapeutic translation, safety, analytics, and manufacturing.
A design-of-experiments approach produced an SM-102-derived formulation with less hepatic reporter expression and preserved or improved expression after local administration. Experiments included intramuscular, intracerebroventricular, and intravitreal routes. Mechanistic analyses associated the change with altered protein binding, systemic exposure, and hepatocyte trafficking. These route-specific results support formulation optimization but do not demonstrate noninvasive access to the brain or eye.
A study designed ionizable lipids specifically for circular RNA, whose topology differs from linear mRNA. Lead lipid iL-19 combined aminoethoxy head groups with doubly branched tails and improved protein expression after intramuscular delivery in mice relative to several benchmark lipids. The results establish preclinical design principles, not clinical superiority.
Journal of controlled release : official journal of the Controlled Release Society
A C12-200-based formulation was optimized for movement and cellular delivery in the protein-poor vitreous environment. It co-delivered RB1 mRNA and triptolide, improving antiproliferative activity and suppressing tumors in an orthotopic retinoblastoma model after intravitreal administration. Retinal evaluations supported tolerability during the study period. The combination remains preclinical and requires longer ocular safety assessment and pediatric translation studies.
Researchers selected eight hemagglutinin sequences to represent circulating swine influenza diversity and evaluated individual and multivalent mRNA vaccines in pigs. The multivalent formulation elicited responses against its component antigens and protected against lung lesions after the tested challenge. This large-animal veterinary study supports adaptable multivalent design, while protection across untested strains and direct relevance to human influenza remain unresolved.
A GEN commentary by a USP principal scientist argues that mRNA development is shifting toward precision delivery across cancer, protein replacement, encoded antibodies, regenerative medicine, and gene editing. It emphasizes reaching appropriate tissues and cell types while limiting unintended exposure. This is an industry perspective on development priorities, not a new clinical readout.
Circular RNA nanoparticles encoding the malaria transmission antigen Pvs25 were compared with a modified linear mRNA vaccine in mice. Both platforms induced antigen-specific responses, and booster immunization generated antibodies that blocked parasite development in mosquito assays. The findings support further evaluation of circular RNA for transmission-blocking vaccination, without establishing greater efficacy, durability, or manufacturing economy than linear mRNA in humans.
Sensible announced a $47 million financing package comprising an Oxford Science Enterprises-led Series A and up to $20 million in non-dilutive funding. Transaction adviser DLA Piper confirmed that proceeds will support VECTOR platform scale-up, AI-enabled sequence design, high-throughput screening, and clinical-grade manufacturing capabilities. The $47 million figure is not a disclosed equity-only round size.
Screening eight ionizable lipids identified a lead formulation that delivered reporter RNA to several immune-cell types. Researchers then used it to engineer primary human T cells expressing a MUC1-directed CAR, with cytotoxic activity against antigen-positive tumor cells in vitro. Animal reporter experiments supported delivery feasibility, but the study does not demonstrate therapeutic CAR-T generation inside patients or animals.
Synthego and Biomay announced a nonexclusive North American marketing and resale collaboration covering CRISPR components and manufacturing services. The offering combines Synthego guide RNA expertise with Biomay’s Cas9, mRNA manufacturing, LNP formulation, and aseptic fill-finish capabilities, including research and cGMP options. This is a commercial supply collaboration rather than a new factory opening or a new medicine approval.
Bio Farma selected Quantoom’s Ntensify platform for Indonesian mRNA vaccine development and completed an initial RNA production run in Bandung using a rabies DNA template. Quantoom reported that the 200 mL in vitro transcription run met predefined criteria. CEPI partly supported platform installation. The milestone concerns manufacturing capability building, not demonstrated vaccine efficacy or authorization for commercial product release.
This review evaluates electrophoresis, chromatography, sequencing, and mass spectrometry for measuring mRNA drug-substance identity, length, concentration, intactness, and purity. It compares throughput, sample preparation, and total analysis time while considering multi-attribute methods used for protein therapeutics. The authors identify opportunities for integrated mRNA analytics, rather than validating a universal platform that replaces all individual quality assays.
4basebio announced clinical-grade enzymatic opDNA starting-material supply for an unnamed multinational pharmaceutical company’s cell therapy program. TriLink was selected as the mRNA development and manufacturing partner, using its CleanCap technology. The collaboration supports an upcoming Phase I program and illustrates coordination between DNA template and mRNA suppliers. The customer and financial terms were undisclosed; no clinical outcomes were reported.
Continue your research
All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.
